MS Bio is set to list on the stock market on the 22nd. Its initial public offering (IPO) price has been fixed at 7,800 won. Its major product lines, including human tissue-derived acellular dermal matrix and bone graft materials, are expected to draw attention following the listing.

■ IPO Schedule... From Preliminary Review Filing to Subscription

According to the IPO schedule, MS Bio filed for a preliminary listing review on April 16 and received approval on July 10. The company then submitted its securities registration statement on September 7 and conducted demand forecasting for institutional investors from September 28 to October 2. Public subscription for retail investors was held over two days from October 12 to 13, followed by the allotment announcement and payment/refund procedures on the 15th.

■ MYDERM... Human Tissue-Derived Acellular Dermal Matrix

MS Bio's key products include MYDERM, a human tissue-derived acellular dermal matrix product, and MYBONE, a human-derived bone graft material.

MYDERM is an acellular dermal matrix product derived from human tissue. It is manufactured through donor screening and tissue processing, with a quality management system that meets the standards of the Ministry of Food and Drug Safety and the American Association of Tissue Banks (AATB). Notably, it is designed to reduce cells and DNA components that could trigger immune responses or transplant rejection through decellularization and purification processes. Another feature is the minimization of fatty components contained in skin tissue using specialized purification and processing technology.

The product is supplied in a Ready To Use (RTU) form that can be used immediately without a separate hydration process. The product line is divided into MYDERM Recon, MYDERM Implant, and MYDERM Graft, depending on the intended use and specifications.

■ MYBONE... Syringe-Type Human-Derived Bone Graft Material

Another key product, MYBONE, is a bone graft material made from human-derived cortical bone powder. Through processes such as delipidization, immunogenic substances are removed, and it is designed to induce new bone formation in bone defect sites by utilizing bone tissue and mineral components. It was developed mainly for application to bone defect areas prior to dental implant placement, and it comes in syringe form for the convenience of medical practitioners. It can be used after rehydration with the patient's blood or saline solution.

The MYBONE product line is divided into MYBONE, composed of 100% cortical bone, and MYBONE Plus, composed of 70% cortical bone and 30% cancellous bone. MYBONE Plus is designed to secure both mechanical stability and biological activity by adding cancellous bone, focusing on enhancing properties necessary for bone regeneration, such as new bone formation, osteoinduction, and vascularization.

■ Stock Price Direction on Listing Day

As such, MS Bio's major product lines consist of dermal matrix products and bone graft materials utilizing human tissue-derived materials. MYDERM is characterized by its tissue purification and processing technology and ease of use, while MYBONE features material composition for bone regeneration and procedural convenience.

Attention is focused on how the stock price will move on the first day of trading, based on the confirmed offer price of 7,800 won. However, since post-listing stock prices are determined in actual trading, the offer price and the post-listing market price should be considered separately.

[This article is intended to provide information for investment reference purposes and does not recommend the purchase or sale of any specific stock. Content is subject to change depending on market conditions. Investment decisions and any resulting responsibility rest with the investor. AI provided partial assistance.]